These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32449966)

  • 1. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
    Mangia A; Milligan S; Khalili M; Fagiuoli S; Shafran SD; Carrat F; Ouzan D; Papatheodoridis G; Ramji A; Borgia SM; Wedemeyer H; Losappio R; Pérez-Hernandez F; Wick N; Brown RS; Lampertico P; Doucette K; Ntalla I; Ramroth H; Mertens M; Vanstraelen K; Turnes J
    Liver Int; 2020 Aug; 40(8):1841-1852. PubMed ID: 32449966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].
    Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
    J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
    Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
    Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
    J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].
    Xu Q; Zhang W; Ma YX; He CN; Zhang LT; Abulitifu Y; Li Y; Wang N; Wang HL; Zhao YY; Gao X; Gao PG; Su XY; Li S; Liu YY; Guo F; Chen ZQ; Liu HL; Gao XQ; Fu JJ; Yu GY; Wang XZ; Wang JP; Zhang YP; Ji FP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Nov; 29(11):1046-1052. PubMed ID: 34933421
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Soria A; Fava M; Bernasconi DP; Lapadula G; Colella E; Valsecchi MG; Migliorino GM; D'Ambrosio R; Landonio S; Schiavini M; Spinetti A; Carriero C; Degasperi E; Cologni G; Gatti F; Viganò P; Hasson H; Uberti-Foppa C; Pasulo L; Baiguera C; Rossotti R; Vinci M; Puoti M; Giorgini A; Menzaghi B; Lombardi A; Pan A; Aghemo A; Grossi PA; Boldizzoni R; Colombo S; Viganò M; Rumi MG; Del Poggio P; Valenti L; Giglio O; De Bona A; d'Arminio Monforte A; Colombo A; Spinelli O; Pigozzi MG; Molteni C; Bonfanti P; Terreni N; Perini P; Capretti A; Bella D; Liani C; Polo S; Aimo G; Pagnucco L; Bhoori S; Centenaro R; Graffeo M; Ciaccio A; Dionigi E; Lazzaroni S; Carderi I; Di Marco M; Rizzardini G; Noventa F; Lampertico P; Fagiuoli S
    Liver Int; 2020 Apr; 40(4):769-777. PubMed ID: 31970845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.
    Mangia A; Cenderello G; Copetti M; Verucchi G; Piazzolla V; Lorusso C; Santoro R; Squillante MM; Orlandini A; Minisini R; Ciancio A
    Cells; 2019 Apr; 8(4):. PubMed ID: 30987413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Chen CY; Su WW; Tseng KC; Lo CC; Liu CJ; Chen JJ; Peng CY; Shih YL; Yang SS; Huang CS; Huang KJ; Chang CY; Tsai MC; Kao WY; Fang YJ; Chen PY; Su PY; Tseng CW; Huang JJ; Lee PL; Lai HC; Hsieh TY; Chang CH; Huang YJ; Lee FJ; Chang CC; Kao JH
    Gut; 2022 Jan; 71(1):176-184. PubMed ID: 33408122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
    J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.
    Liu CH; Chen PY; Chen JJ; Lo CC; Su WW; Tseng KC; Liu CJ; Huang CS; Huang KJ; Yang SS; Peng CY; Tsai MC; Kao WY; Chang CY; Shih YL; Fang YJ; Chen CY; Lee PL; Huang JJ; Su PY; Tseng CW; Hung CC; Chang CH; Huang YJ; Lai HC; Chang CC; Lee FJ; Hsieh TY; Kao JH
    Hepatol Int; 2021 Apr; 15(2):338-349. PubMed ID: 33677787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
    Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
    Han Q; Fan X; Wang X; Wang Y; Deng H; Zhang X; Zhang K; Li N; Liu Z
    Virol J; 2019 Jun; 16(1):74. PubMed ID: 31159813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
    J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.